A high-stakes legal feud between Chinese appliance titan Haier Group and a controversial 'Beauty Queen' has exposed a murky underworld of pseudo-scientific anti-aging treatments and questionable corporate governance. The dispute centers on Yu Wenhong, the founder of the Yumeiren international cosmetic surgery empire, and her claims of a strategic partnership with Haier for 'blood-changing' rejuvenation therapies. While Haier has issued a stern denial of any such business involvement, the reality of their joint investment in a high-end hospital suggests a relationship far more entangled than the conglomerate admits.
At the heart of the scandal is the Chengdu Xunshang Perennial Hospital, a facility marketed as a 'longevity clinic' for China's ultra-wealthy. Investigation into the hospital's ownership reveals a complex structure where Haier indirectly holds a 24% stake. The facility has become a hub for controversial procedures, including 'blood purification' and the injection of 'young proteins' purportedly harvested from male donors aged 17 to 21. These treatments, which carry price tags ranging from hundreds of thousands to millions of yuan, promise to 'reverse' menopause and reset the biological clock.
The most alarming revelation involves the hospital's operational lead, a mysterious figure known as Dale Li. Far from the Cambridge-educated doctor he claims to be, investigative records suggest Li is actually Li Liang, a man with a notorious criminal past. Known in Hong Kong media as the 'Master of Disguise' fugitive, Li famously escaped custody in 2018 by climbing through a hospital ceiling. His transition from a wanted fraudster to the chairman of a Haier-backed medical institution raises grave questions about the due diligence performed by one of China's most respected global brands.
While Haier’s financial arm, Haier Jinkong, attempts to litigate its way out of the reputational fallout, the 'Beauty Queen' Yu Wenhong has countersued for a symbolic one yuan, alleging Haier is unfairly distancing itself from a legitimate business partnership. The hospital itself maintains a dual identity: officially distancing itself from Yu’s wilder claims in corporate filings, while simultaneously serving as the primary execution site for her 'Forever Young' marketing campaigns. This strategic ambiguity allows questionable medical practices to flourish under the borrowed prestige of a Fortune 500 brand.
This incident highlights the systemic risks within China’s 'Big Health' sector, where industrial giants have rushed to diversify into healthcare. To quickly scale these asset-heavy ventures, conglomerates often partner with third-party operators who prioritize aggressive marketing over clinical rigor. In this case, the pursuit of high-net-worth 'longevity' dollars has led Haier into a partnership with individuals whose backgrounds and medical claims would likely fail even the most basic regulatory or ethical scrutiny in more transparent markets.